REFERENCES
1- Steg PG, James SK, Atar D, et al. ESC Guidelines
for the management of acute myocardial infarction in patients presenting
with ST-segment elevation: The Task Force on the management of
ST-segment elevation ac te myocardial infarction of the European Society
of Cardiology (ESC). Eur Heart J. 2012;33:2569–619.
2-Zeymer U, Huber K, Fu Y, et al.; for the ASSENT-4
PCI Investigators. Impact of TIMI 3 patency before primary percutaneous
coronary intervention for ST-elevation myocardial infarction on clinical
outcome: Results from the ASSENT-4 PCI study. Eur Heart J Acute
Cardiovasc Care 2012; 1: 136–142.
3-Bisoendial RJ, Boekholdt SM, V rgeer M, et al.
C-reactive protein is a mediator of cardiovascular disease. Eur Heart J.
2010;31:2087–91.
4-Bisoendial RJ, Kast l in JJP, Peters SLM, et al.
Effects of CRP infusion on endothelial function and coagulation in
normocholesterolemic and hypercholesterolemic subjects. J Lipid Res.
2007;48:952–60.
5-Oduncu V, Erkol A, Karabay CY, et al. The prognostic
value of serum albumin levels on admission in patients with acute
ST-segment elevation myocardial infarction undergoing a primary
percutaneous coronary intervention. Coron Artery Dis. 2013;24:88–94
6-Fairclough E, Cairns E, Hamilton J, et al.
Evaluation of a modified early warning system for acute medical
admissions and comparison with C-reactive protein/albumin ratio as a
predictor of patient outcome. Clinical medicine. 2009;9(1):30-33.
7-Kinoshita A, Onoda H, Imai N, et al. The C-reactive
protein/albumin ratio, a novel inflammation-based prognostic score,
predicts outcomes in patients with hepatocellular carcinoma. Annals of
surgical oncology. 2015;22(3):803-810.
8-Fairclough E, Cairns E, Hamil on J, et al.
Evaluation of a modified early warning system for acute medical
admissions and comparison with C-reactive protein/albumin ratio as a
predictor of patient outcome. Clin Med (Lond). 2009;9:30–3.
9-Kinoshita A, Onoda H, Imai N, et al. The C-reactive
protein/albumin ratio, a novel inflammation-based prognostic score,
predicts outcomes in patients with hepatocellular carcinoma. Ann
SurgOncol.2015;22:803–10.
10-Nallamothu BK, Normand SL, Wang Y, et al. Relation
between door-to-balloon times and mortality after primary percutaneous
coronary intervention over time: a retrospective study. Lancet
2015;385:1114-22.
11- Zeymer U, Huber K, Fu Y, et al.; for the ASSENT-4
PCI Investigators. Impact of TIMI 3 patency before primary percutaneous
coronary intervention for ST-elevation myocardial infarction on clinical
outcome: Results from the ASSENT-4 PCI study. Eur Heart J Acute
Cardiovasc Care 2012; 1: 136–142.
12-Rakowski T, Dudek D, Dziewierz A, et al. Impact of
infarct-related artery patency before primary PCI on outcome in patients
with ST-segment elevation myocardial infarction: The HORIZONS-AMI trial.
Eurointervention 2013; 8: 1307–1314.
13-Christopoulos C, Farag M, Sullivan K, et al.
Impaired thrombolytic status predicts adverse cardiac events in patients
undergoing primary percutaneous coronary intervention. Thromb. Haemost.
2017;117(3): 457–70.
14- Stefanadis C, Diamantopoulos L, Vlachopoulos C, et
al. Thermal heterogeneity within human atherosclerotic coronary arteries
detected in vivo: a new method of detection by application of a special
thermography catheter. Circulation 1999;99:1965-71.
15- Fayad ZA, Fuster V, Fallon JT, et al. Noninvasive
in vivo human coronary artery lumen and wall imaging using black-blood
magnetic resonance imaging. Circulation 2000;102:506-10.
16- Kottoor SJ, Arora RR. The utility of
anti-inflammatory agents in cardiovascular disease: a novel perspective
on the treatment of atherosclerosis. J Cardiovasc Pharmacol Ther.
2018-107424841877854
17-Biasucci LM, D’Onofrio G, Liuzzo G, et al.
Intracellular neutrophil myeloperoxidase is reduced in unstable angina
and myocardial infarction, but its reduction is not related to ischemia.
J Am Coll Cardiol 1996;27:611-6.
18-Buffon A, Biasucci LM, Liuzzo G, et al. Widespread
coronary inflammation in unstable angina. N Engl J Med 2002;347: 5-12.
19-Barrett TO, Hennan JK, Marks RM, et al. C-reactive-
protein-associated increase in myocardial infarct size after
ischemia/reperfusion. J Pharnıacol Exp Ther2002;303: ı 007-13
20-Pietila K, Harnıoinen A, Poyhonen L, et al.
Intravenous streptokinase treatment and serum C-reactive protein in
patients wiıh acute nıyocardial infarction. Br Hearı J 1987;58:225-9
21- Pietila K, Harmoinen A, Hermens W, et al. Serum
C-reactive protein and infarct size in myocardial infarct patients wiıh
a closed versus an open infarct-related coronary arıery after
thrombolytic therapy. Eur Heart J 1993; 14:915-9
22- Doganay B., Okutucu S., Cetin M. Et al Association
of Serum Copeptin Levels with Patency of Infarct-Related Arteries in
Patients with ST-Segment Elevation Myocardial Infarction. Acta Cardiol
Sin 2019;35:360 368 DOI: 10.6515/ACS.201907_35(4).20181101A
23- Jing Li, Ying Zhou, Yaowen Zhang et al Admission
homocysteine is an independent predictor of spontaneous reperfusion and
early infarct-related artery patency before primary percutaneous
coronary intervention in ST-segment elevation myocardial infarction. Li
et al. BMC Cardiovascular Disorders (2018) 18:125
https://doi.org/10.1186/s12872-018-0868-3
24-Cınar T. Cagdaş M. Rencüzogulları İ. et al
Prognostic Efficacy of C-reactive Protein/Albumin Ratio in ST-Elevation
Myocardial Infarction. Scand Cardiovasc J DOI:
10.1080/14017431.2019.1590628. Epub 2019 Apr 3.
25-Karabag Y, Cagdas M, Rencuzogullari I, et al.
Relationship between C-reactive protein/albumin ratio and coronary
artery disease severity in patients with stable angina pectoris. J.
Clin. Lab. Anal. 32(7), e22457 (2018).
26- Wang W, Ren D, Wang CS et al Prognostic Efficacy
of High-Sensitivity C-reactive Protein to Albumin Ratio in Patients With
Acute Coronary Syndrome. Biomark Med. 2019 Jul;13(10):811-820. DOI:
10.2217/bmm-2018-0346. Epub 2019 May 30.
27- Karabag Y, Cagdas¸ M, Rencuzogullari I, et al.
Usefulness of the C-reactive protein/albumin ratio for predicting
no-reflow in ST-elevation myocardial infarction treated with primary
percutaneous coronary intervention. Eur. J. Clin. Invest. 48(6), e12928
(2018).
28-Sianos G, Papafaklis MI, Serruys PW. Angiographic
thrombus burden classification in patients with ST-segment elevation
myo-cardial infarction treated with percutaneous coronary interven-tion.
J Invasive Cardiol. 2010;22(10):6B-14B.
29-Singh M, Berger PB, Ting HH, et al. Influence of
coronary throm-bus on outcome of percutaneous coronary angioplasty in
the cur-rent era (the Mayo Clinic experience). Am J Cardiol. 2001;
88(10):1091-1096.